878799-19-0

Basic information

• Product Name: Carbamic acid, [3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methylpropyl]-, phenylmethyl ester
• CAS NO: 878799-19-0
• Molecular Formula: C17H26N2O4
• Molecular Weight: 322.404
• Mol File: 878799-19-0.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methylpropyl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methylpropyl]-, phenylmethyl ester(878799-19-0)
• EPA Substance Registry System: Carbamic acid, [3-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methylpropyl]-, phenylmethyl ester(878799-19-0)

Safety Data

• Hazardous Substances Data: 878799-19-0(Hazardous Substances Data)

Upstream product

• 701255-53-0 tert-butyl (4-aminopentyl)carbamate 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 878799-20-3 tert-butyl (3-aminobutyl)carbamate 
• 168828-15-7 benzyl (3-amino-1-methylpropyl)carbamate 

Relevant articles and documents

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

ACYCLIC 1,3-DIAMINES AND USES THEREFOR

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted -acyclic diamines according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein: the R groups are as defined herein. The present invention also relates to a pharmaceutical composition and a method of treatment using the compound of Formula (I).